Angina News and Research RSS Feed - Angina News and Research

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.
Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want to know why this research isn't more widely used. [More]
Scientists identify defects in colossal heart protein which leads to stroke, heart failure

Scientists identify defects in colossal heart protein which leads to stroke, heart failure

The landmark discovery of a tiny defect in a vital heart protein has for the first time enabled heart specialists to accurately pinpoint a therapeutic target for future efforts in developing a drug-based cure for cardiovascular diseases. [More]
Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

ACS is currently identified through the use of ECGs pre-hospital and the confirmed via a Troponin biomarker test once in the acute setting. [More]
Studies evaluate traditional management of heart attack patients after discharge from hospital

Studies evaluate traditional management of heart attack patients after discharge from hospital

Beta-blockers have been a cornerstone in the treatment of heart attack survivors for more than a quarter of a century. However, many of the data predate contemporary medical therapy such as reperfusion, statins, and antiplatelet agents, and recent data have called the role of beta-blockers into question. [More]
Women delay seeking medical care for heart symptoms, put health at risk

Women delay seeking medical care for heart symptoms, put health at risk

When heart symptoms strike, men and women go through similar stages of pain but women are more likely to delay seeking care and can put their health at risk, according to a study presented at the Canadian Cardiovascular Congress. [More]
Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
South Asians in Canada have higher rate of heart disease compared with white people

South Asians in Canada have higher rate of heart disease compared with white people

South Asians living in Canada have a higher rate of heart disease and double the rate of diabetes compared with while people, McMaster researchers have found. [More]
Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. [More]
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests. [More]

FFR guided drug-eluting stenting reduces death compared to medical therapy in stable CAD patients

Fractional flow reserve (FFR)-guided drug-eluting stenting reduces death, myocardial infarction or urgent revascularisation, as compared to medical therapy in patients with stable coronary artery disease (CAD), according to the results of the FAME 2 trial presented for the first time today at ESC Congress by principal investigator Dr Bernard De Bruyne (Belgium). [More]
Darapladib drug fails to reduce risk of recurrent major coronary events

Darapladib drug fails to reduce risk of recurrent major coronary events

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent major coronary events, according to a study published by JAMA. [More]
Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy reduces the risk of cardiovascular (CV) events, strokes and mortality in hypertensive older adults, according to research presented at ESC Congress 2014 today by Dr Maciej Ostrowski from Poland. [More]
Study suggests that energy drinks can cause heart problems

Study suggests that energy drinks can cause heart problems

Energy drinks can cause heart problems according to research presented at ESC Congress 2014 today by Professor Milou-Daniel Drici from France. [More]
ESC Guidelines on diagnosis and treatment of aortic diseases published in European Heart Journal

ESC Guidelines on diagnosis and treatment of aortic diseases published in European Heart Journal

The first comprehensive ESC Guidelines on aortic diseases are published today. They are presented at ESC Congress 2014 by Task Force Chairpersons Professor Raimund Erbel (Germany) and Professor Victor Aboyans (France). [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). [More]
First Edition: August 19, 2014

First Edition: August 19, 2014

Today's early morning highlights from the major news organizations, including stories about a how a hospital system's data was hacked, involving as many as 4.5 million patients' records. [More]
Researchers compare benefits of bivalirudin and heparin for patients undergoing coronary stenting

Researchers compare benefits of bivalirudin and heparin for patients undergoing coronary stenting

Bivalirudin and heparin are two anticoagulant options for patients undergoing coronary stenting for ischemic heart disease. Bivalirudin, a newer anticoagulant, has been touted as being as effective as generic heparin, but with nearly half the rate of bleeding. [More]